QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.105.083501v1 315/3/1247    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hansen, R. J. Articles by Dolan, M. E. Search for Related Content PubMed PubMed Citation Articles by Hansen, R. J. Articles by Dolan, M. E.

CHEMOTHERAPY, ANTIBIOTICS, AND GENE THERAPY

Role of O⁶-Alkylguanine-DNA Alkyltransferase in Protecting against 1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU)-Induced Long-Term Toxicities

Committee on Cancer Biology (R.J.H., M.E.D.), Departments of Medicine (M.E.D.), Pediatrics (R.N.), and Health Studies (S.L.) and Cancer Research Center, University of Chicago (R.J.H., R.N., S.M.D., M.M.C., S.L., M.E.D.), Chicago, Illinois; and Department of Laboratory Medicine, University of California, San Francisco, California (S.C.K.)

O⁶-alkylguanine-DNA alkyltransferase (AGT) protects from the mutagenic and toxic lesions induced by 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), and in many tumors, AGT overexpression provides a means of resistance. To circumvent this, O⁶-benzylguanine, an inactivator of AGT, has been developed and is currently in clinical development with BCNU; however, the potential long-term toxicities associated with this treatment are unknown. With the inactivation of AGT by O⁶-benzylguanine, a higher number of toxic and mutagenic O⁶-alkylguanine lesions introduced by methylating or chloroethylating agents would be expected. In this study, cohorts of mice were treated with vehicle, O⁶-benzylguanine (30 mg/kg), BCNU alone (low dose of 15 mg/kg or high dose of 50 mg/kg), or O⁶-benzylguanine (30 mg/kg) plus BCNU (15 mg/kg) and followed for 12 months post-treatment. Mice treated with O⁶-benzylguanine plus BCNU or high-dose BCNU died significantly earlier (p < 0.0001) than mice in the other three cohorts with a median survival of 8.3 (O⁶-benzylguanine plus BCNU) and 7.9 months (high-dose BCNU). Histopathologic sections of tissues revealed that the most common morphological diagnosis in animals treated with O⁶-benzylguanine plus BCNU (15 mg/kg) or BCNU (50 mg/kg) was cytomegaly in the lung with greater severity observed in mice receiving the combination O⁶-benzylguanine plus BCNU. Four of five mice analyzed in this cohort had alveolar histiocytosis, with one also having alveolar edema. In contrast, liver and kidney toxicity was only observed in mice treated with BCNU (50 mg/kg). These results suggest that O⁶-benzylguanine enhances long-term pulmonary toxicity associated with BCNU in mice.

Address correspondence to: Dr. M. Eileen Dolan, Section of Hematology/Oncology, 5841 S. Maryland Ave., Box MC2115, The University of Chicago, Chicago, IL 60637. E-mail: edolan{at}medicine.bsd.uchicago.edu

This article has been cited by other articles:

				R. Nagasubramanian, R. J. Hansen, S. M. Delaney, M. M. Cherian, L. D. Samson, S. C. Kogan, and M. E. Dolan Survival and tumorigenesis in O6-methylguanine DNA methyltransferase-deficient mice following cyclophosphamide exposure Mutagenesis, September 1, 2008; 23(5): 341 - 346. [Abstract] [Full Text] [PDF]

				R. J. Hansen, R. Nagasubramanian, S. M. Delaney, L. D. Samson, and M.E. Dolan Role of O6-methylguanine-DNA methyltransferase in protecting from alkylating agent-induced toxicity and mutations in mice Carcinogenesis, May 1, 2007; 28(5): 1111 - 1116. [Abstract] [Full Text] [PDF]